Erin M Parry1, Dustin L Gable2, Susan E Stanley2, Sara E Khalil3, Valentin Antonescu4, Liliana Florea4, Mary Armanios5. 1. Osler Medical Housestaff Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: marmani1@jhmi.edu.
Abstract
INTRODUCTION: Although lung cancer is generally thought to be environmentally provoked, anecdotal familial clustering has been reported, suggesting that there may be genetic susceptibility factors. We systematically tested whether germline mutations in eight candidate genes may be risk factors for lung adenocarcinoma. METHODS: We studied lung adenocarcinoma cases for which germline sequence data had been generated as part of The Cancer Genome Atlas project but had not been previously analyzed. We selected eight genes, ATM serine/threonine kinase gene (ATM), BRCA2, DNA repair associated gene (BRCA2), checkpoint kinase 2 gene (CHEK2), EGFR, parkin RBR E3 ubiquitin protein ligase gene (PARK2), telomerase reverse transcriptase gene (TERT), tumor protein p53 gene (TP53), and Yes associated protein 1 gene (YAP1), on the basis of prior anecdotal association with lung cancer or genome-wide association studies. RESULTS: Among 555 lung adenocarcinoma cases, we detected 14 pathogenic mutations in five genes; they occurred at a frequency of 2.5% and represented an OR of 66 (95% confidence interval: 33-125, p < 0.0001 [chi-square test]). The mutations fell most commonly in ATM (50%), followed by TP53, BRCA2, EGFR, and PARK2. Most (86%) of these variants had been reported in other familial cancer syndromes. Another 12 cases (2%) carried ultrarare variants that were predicted to be deleterious by three protein prediction programs; these most frequently involved ATM and BRCA2. CONCLUSIONS: A subset of patients with lung adenocarcinoma, at least 2.5% to 4.5%, carry germline variants that have been linked to cancer risk in Mendelian syndromes. The genes fall most frequently in DNA repair pathways. Our data indicate that patients with lung adenocarcinoma, similar to other solid tumors, include a subset of patients with inherited susceptibility.
INTRODUCTION: Although lung cancer is generally thought to be environmentally provoked, anecdotal familial clustering has been reported, suggesting that there may be genetic susceptibility factors. We systematically tested whether germline mutations in eight candidate genes may be risk factors for lung adenocarcinoma. METHODS: We studied lung adenocarcinoma cases for which germline sequence data had been generated as part of The Cancer Genome Atlas project but had not been previously analyzed. We selected eight genes, ATM serine/threonine kinase gene (ATM), BRCA2, DNA repair associated gene (BRCA2), checkpoint kinase 2 gene (CHEK2), EGFR, parkin RBR E3 ubiquitin protein ligase gene (PARK2), telomerase reverse transcriptase gene (TERT), tumor protein p53 gene (TP53), and Yes associated protein 1 gene (YAP1), on the basis of prior anecdotal association with lung cancer or genome-wide association studies. RESULTS: Among 555 lung adenocarcinoma cases, we detected 14 pathogenic mutations in five genes; they occurred at a frequency of 2.5% and represented an OR of 66 (95% confidence interval: 33-125, p < 0.0001 [chi-square test]). The mutations fell most commonly in ATM (50%), followed by TP53, BRCA2, EGFR, and PARK2. Most (86%) of these variants had been reported in other familial cancer syndromes. Another 12 cases (2%) carried ultrarare variants that were predicted to be deleterious by three protein prediction programs; these most frequently involved ATM and BRCA2. CONCLUSIONS: A subset of patients with lung adenocarcinoma, at least 2.5% to 4.5%, carry germline variants that have been linked to cancer risk in Mendelian syndromes. The genes fall most frequently in DNA repair pathways. Our data indicate that patients with lung adenocarcinoma, similar to other solid tumors, include a subset of patients with inherited susceptibility.
Authors: Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber Journal: Nat Genet Date: 2005-10-30 Impact factor: 38.330
Authors: Adi Gazdar; Linda Robinson; Dwight Oliver; Chao Xing; William D Travis; Junichi Soh; Shinichi Toyooka; Lori Watumull; Yang Xie; Kemp Kernstine; Joan H Schiller Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609
Authors: Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan Journal: Nat Genet Date: 2009-11-29 Impact factor: 38.330
Authors: Shih-Jen Hwang; Li Shu-Chung Cheng; Guillermina Lozano; Christopher I Amos; Xiangjun Gu; Louise C Strong Journal: Hum Genet Date: 2003-06-11 Impact factor: 4.132
Authors: Krishna L Kanchi; Kimberly J Johnson; Charles Lu; Michael D McLellan; Mark D M Leiserson; Michael C Wendl; Qunyuan Zhang; Daniel C Koboldt; Mingchao Xie; Cyriac Kandoth; Joshua F McMichael; Matthew A Wyczalkowski; David E Larson; Heather K Schmidt; Christopher A Miller; Robert S Fulton; Paul T Spellman; Elaine R Mardis; Todd E Druley; Timothy A Graubert; Paul J Goodfellow; Benjamin J Raphael; Richard K Wilson; Li Ding Journal: Nat Commun Date: 2014 Impact factor: 14.919
Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Semanti Mukherjee; Chaitanya Bandlamudi; Matthew D Hellmann; Yelena Kemel; Esther Drill; Hira Rizvi; Kaitlyn Tkachuk; Aliya Khurram; Michael F Walsh; Marjorie G Zauderer; Diana Mandelker; Sabine Topka; Ahmet Zehir; Preethi Srinivasan; Myvizhi Esai Selvan; Maria I Carlo; Karen A Cadoo; Alicia Latham; Jada G Hamilton; Ying L Liu; Steven M Lipkin; Sami Belhadj; Gareth L Bond; Zeynep H Gümüş; Robert J Klein; Marc Ladanyi; David B Solit; Mark E Robson; David R Jones; Mark G Kris; Joseph Vijai; Zsofia K Stadler; Christopher I Amos; Barry S Taylor; Michael F Berger; Charles M Rudin; Kenneth Offit Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Karen L Reckamp; Carolyn E Behrendt; Thomas P Slavin; Stacy W Gray; Danielle K Castillo; Marianna Koczywas; Mihaela C Cristea; Kirsten M Babski; Donna Stearns; Catherine A Marcum; Yenni P Rodriguez; Amie J Hass; Mary M Vecchio; Pamela Mora; Aleck E Cervantes; Sharon R Sand; Rosa M Mejia; Terrence C Tsou; Ravi Salgia; Jeffrey N Weitzel Journal: Cancer Date: 2021-04-15 Impact factor: 6.921
Authors: Myvizhi Esai Selvan; Marjorie G Zauderer; Charles M Rudin; Siân Jones; Semanti Mukherjee; Kenneth Offit; Kenan Onel; Gad Rennert; Victor E Velculescu; Steven M Lipkin; Robert J Klein; Zeynep H Gümüş Journal: J Thorac Oncol Date: 2020-08-28 Impact factor: 15.609